Technology
Health
Biotechnology

IMV

179

$2.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-1.41%) As of 1:22 PM EST today
-$0.04 (-1.41%) Today

Why Robinhood?

You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!

About IMV

IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Read More Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.

CEO
Frederic Ors
Employees
—
Headquarters
Dartmouth, Nova Scotia
Founded
2000
Market Cap
143.23M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
13.91K
High Today
$2.98
Low Today
$2.71
Open Price
$2.98
Volume
9.28K
52 Week High
$6.02
52 Week Low
$2.11

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2018 IPO

IMV News

Financial PostDec 8

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology Annual Meeting

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses Reproducible survivin-specific T cell r
31

IMV Earnings

-$0.13
-$0.11
-$0.10
-$0.08
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
—

You May Also Like

VGK
NVTA
IBDR
MTG
CTRM
KEX
SLGL
SNA
GRAF=
SKOR
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy IMV

Market Price$2.79
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell IMV stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up